Metformin Users Show Lower Mortality After COVID-19 in Large Observational Study

Key points

• The Stanford-led analysis reviewed medical records of 53,332 U.S. adults with type 2 diabetes who tested positive for COVID-19 between October 2021 and November 2023.
• Patients taking metformin had a 39% lower risk of death over the following year compared to those prescribed DPP-4 inhibitors, after adjusting for age, gender, and other variables.
• Researchers noted that metformin may regulate biological pathways related to blood pressure and fluid balance, which can influence COVID-19 severity, and may reduce inflammation and viral levels.
• An independent epidemiologist highlighted that patients on metformin are generally younger and healthier than those on DPP-4 inhibitors, which are often reserved for older patients or those with kidney disease.
• While initial data suggested a 13% drop in long COVID symptoms among metformin users, further statistical testing found no significant link, and the study lacked complete vaccination data.

Background

Metformin remains the standard first-line treatment for type 2 diabetes, though recent studies have compared it with newer GLP-1 receptor agonists for prediabetes prevention. Other research has also explored how common diabetes medications can lead to unnecessary prescribing cascades due to side effects. These new findings add to a growing body of evidence examining the broader health impacts of diabetes medications beyond blood sugar management.

How outlets are covering it

Fox News and Mezha.net reported on the Stanford study, emphasizing the 39% lower mortality risk but highlighting the observational nature of the data and the health disparities between the two drug groups. News-Medical focused on a separate study from the Journal of Medical Virology, which found that prescribing metformin within six days of infection was associated with a 53% lower risk of long COVID or death over six months. While both outlets agree on the potential benefits, they differ in their focus: Fox News and Mezha.net stress the limitations of the observational data and the need for randomized trials, whereas News-Medical highlights the timing of the prescription and its correlation with reduced long-term symptoms. All sources agree that more clinical trials are needed to confirm these findings and that patients should not alter their current medications based on these studies.

Why it matters

These findings suggest that metformin, a widely prescribed and inexpensive diabetes drug, may offer additional protective benefits during viral infections. However, the observational nature of the studies means that causation cannot be established, and the differences in patient health between the two drug groups complicate the interpretation. Patients should continue to follow their doctors' advice and not change their medications based on these preliminary findings.

What to watch

Researchers and experts are calling for large, well-designed randomized clinical trials to confirm the potential benefits of metformin in reducing COVID-19 mortality and long COVID symptoms. Until such trials are completed, the current evidence is not sufficient to change treatment guidelines or patient behavior.